Gossamer Bio, Inc. GOSS
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 53.29M | 55.54M | 48.47M | 44.05M | 40.24M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 53.29M | 55.54M | 48.47M | 44.05M | 40.24M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 53.29M | 55.54M | 48.47M | 44.05M | 40.24M |
| SG&A Expenses | 47.94M | 47.72M | 37.63M | 36.12M | 35.23M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 211.90M | 226.85M | 211.72M | 197.39M | 185.86M |
| Operating Income | -158.62M | -171.31M | -163.25M | -153.34M | -145.62M |
| Income Before Tax | -125.31M | -180.48M | -170.46M | -158.57M | -142.29M |
| Income Tax Expenses | -88.00K | -88.00K | -88.00K | -2.41M | -3.54M |
| Earnings from Continuing Operations | -125.22 | -180.40 | -170.37 | -156.16 | -138.74 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -125.22M | -180.40M | -170.37M | -156.16M | -138.74M |
| EBIT | -158.62M | -171.31M | -163.25M | -153.34M | -145.62M |
| EBITDA | -158.60M | -171.29M | -163.23M | -153.22M | -145.29M |
| EPS Basic | -45.32 | -63.01 | -59.99 | -54.98 | -48.94 |
| Normalized Basic EPS | -34.54 | -38.75 | -36.86 | -36.13 | -34.25 |
| EPS Diluted | -55.67 | -63.14 | -60.12 | -55.10 | -49.07 |
| Normalized Diluted EPS | -34.43 | -38.75 | -36.86 | -36.13 | -34.25 |
| Average Basic Shares Outstanding | 12.61M | 11.45M | 11.36M | 11.36M | 11.34M |
| Average Diluted Shares Outstanding | 12.72M | 11.45M | 11.36M | 11.36M | 11.34M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |